The Ohio State University Center for Clinical and Translational Science's (CCTS) Optimizing Innovation, Commercialization and Entrepreneurship of Biomedical Research program, in partnership with the Corporate Engagement Office and Nationwide Children's Hospital's Office of Technology Commercialization, is highlighting experts who are working together at an unprecedented pace to fight against COVID-19 on the front lines of innovation.
Messenger RNA (mRNA)-based vaccine is one of the leading candidates for fighting against COVID-19. In our work, we systematically investigated the untranslated regions (UTRs) of mRNAs in order to enhance antigen production. Through a comprehensive analysis and engineering of UTRs, we identified the optimal UTR sequences, termed as NASAR, which significantly enhanced the production of SARS-CoV-2 antigens. The NASAR mRNA encoding SARS-CoV-2 antigens induced strong immune responses in mice. More importantly, this novel mRNA-based platform provide broad applicability to a wide variety of therapeutic applications.
Title: "Constructing a COVID-19 Vaccine"
- Chunxi Zeng, PhD, College of Pharmacy
- Yizhou Dong, PhD, College of Pharmacy
- Paul Stoodley, PhD, Campus Microscopy and Imaging Facility
- Jeffrey Chalmers, PhD, Flow Cytometry Shared Resource
- Amanda Ewart Toland, PhD, FACMG, Genomics Shared Resource
- Richard K. Wilson, PhD, Genomics Shared Resource